Agios Pharmaceuticals, Inc. (AGIO): Total Liabilities
$104.11M
As of 2025-12-31
$82.40M
As of 2026-06-30
-8.9%
3-year compound annual growth
-25.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $104.11M | -14.8% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $122.24M | -3.1% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $126.10M | -8.6% | 2025-02-13, Balance as of period end |
| 2022-12-31 | $137.90M | -5.4% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $145.76M | -67.9% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $453.45M | +81.2% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $250.21M | +46.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $170.92M | -28.5% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $238.89M | -8.3% | 2019-02-14, Balance as of period end |
| 2016-12-31 | $260.50M | n/a | 2018-02-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $104.11M | -14.8% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $4.58M | -34.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
Compare AGIO, QTTB, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗